Therapeutic antibodies against SARS-CoV-2 based on camelid nanobodies

- The invention includes a panel of nanobodies (MW ≈ 14 KDa) clones and human IgG1 heavy chain Fc-fused molecules (MW ≈ 80 KDa). - The molecules have been humanized and can be expressed in mammalian-cells and purified from culture media. - The antibodies have shown potent neutralization capacity for different SARS-CoV-2 virus variants (alpha, beta, gamma and delta). - The monovalent molecules have very high affinity (subnanomolar range) to receptor binding domain (RBD) of spike SARS-CoV-2 protein and compete with the RBD-ACE2 human receptor interaction. - A cocktail based on two of antibodies identified have the potential to become a new therapy against SARS-CoV-2 variants for immunocompromised or high-risk severe disease subjects.